Brossard, April 30, 2026 – Through its partnership with Dr. Reddy’s, Mantra Pharma is proud to be the first company to receive a Notice of Compliance (NOC) from Health Canada for REDDY-Semaglutide, a generic of Ozempic®.

Mantra Pharma also confirms the launch of REDDY Semaglutide in the Quebec market.

This milestone expands Mantra Pharma’s product portfolio and reflects its ongoing commitment—over the past 20 years—to providing high-quality, accessible solutions and supporting pharmacists as a trusted partner.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. For more information, log on to: www.drreddys.com.

About Mantra Pharma

Mantra Pharma develops and markets generic drugs, natural health products, and over-the-counter non-prescription products. It also distributes its own brands (such as mcal, Denta, Eczederm, Urederma and Cutibase) in pharmacies across Quebec and Canada. The company operates from two locations, in Lévis and Brossard, and employs nearly 150 people.